Patents Assigned to Novartis G
-
Patent number: 9763929Abstract: The invention relates to certain nicotine chewing gums that provide for a high rate of buccal absorption and high plasma concentrations, in particular over the first 10 minutes after administration, in a subject willing to quit smoking.Type: GrantFiled: October 31, 2016Date of Patent: September 19, 2017Assignee: Novartis, A.G.Inventors: Markus Rudolph, Giovanna Marzano, Isabelle Rault
-
Patent number: 9572773Abstract: The layered drug delivery devices of the present invention have an outer side and an inner side. The device includes, in order from the outer side to the inner side, a first layer and a second layer. The first layer wherein the first layer is water insoluble, water swellable, and water permeable. The second layer includes a therapeutic amount of a water soluble drug and a water soluble mucoadhesive film. The second layer is disposed such that water passing through said first layer solubilizes the drug. The said solubilized drug then can permeate through a mucosal membrane when the inner side is in contact with the mucosal membrane. The drug delivery device is in sheet form.Type: GrantFiled: April 26, 2010Date of Patent: February 21, 2017Assignee: Novartis A.G.Inventors: Daniel Dormady, Steve Jurgens
-
Patent number: 9511021Abstract: The invention relates to certain nicotine chewing gums that provide for a high rate of buccal absorption and high plasma concentrations, in particular over the first 10 minutes after administration, in a subject willing to quit smoking.Type: GrantFiled: May 19, 2009Date of Patent: December 6, 2016Assignee: Novartis, A.G.Inventors: Markus Rudolph, Giovanna Marzano, Isabelle Rault
-
Patent number: 8158855Abstract: Plants are produced that express an amino acid sequence that, when administered to a fish, produce an antigenic or immune response in the fish. The amino acid sequence in one embodiment is an antigen from an organism that causes pathology in fish. The plant tissue may be fed to the fish, or mixed with other materials and fed to fish, or extracted and administered to the fish.Type: GrantFiled: November 15, 2007Date of Patent: April 17, 2012Assignees: ProdiGene, Inc., Novartis A.G.Inventors: Linda Bootland, Katherine Beifuss
-
Patent number: 8034803Abstract: The invention relates to the selection and treatment of subjects afflicted with occult choroidal neovascular lesions, including subjects with age-related macular degeneration, by use of photo dynamic therapy (PDT).Type: GrantFiled: February 6, 2002Date of Patent: October 11, 2011Assignees: QLT Inc., Novartis, A.G.Inventors: H. Andrew Strong, Mohammad Azab, Yong Hao, John Miller Koester, Troy Albert Reaves, Jr.
-
Patent number: 7652061Abstract: Compounds of the formula provide pharmacological agents which bind to Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the instant invention are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Such conditions include dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, inflammatory bowel diseases, ulcerative colitis, Crohn's disease, and conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X.Type: GrantFiled: May 19, 2004Date of Patent: January 26, 2010Assignee: Novartis A.G.Inventors: Gary Michael Ksander, Thalaththani Ralalage Vedananda
-
Patent number: 7652044Abstract: Provided are 5-membered heterocycle-based p38 kinase, including p38? and p38? kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.Type: GrantFiled: June 2, 2004Date of Patent: January 26, 2010Assignee: Novartis A.G.Inventors: Qing Dong, Fabrice Pierre, Jianqiang Wang
-
Patent number: 7151106Abstract: The invention relates to a new crystalline form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of formula 1, which may be used for example for tumor therapy.Type: GrantFiled: November 16, 2001Date of Patent: December 19, 2006Assignee: Novartis A.G.Inventor: Pekka Hayry
-
Patent number: 6939487Abstract: A method and apparatus for removing a polymeric contact lens from a mold comprising lowering the temperature of the contact lens with a cryogenic material, such as liquid nitrogen, to a temperature and for a time sufficient for the lens to release from the mold without the application of external forces.Type: GrantFiled: October 13, 2000Date of Patent: September 6, 2005Assignee: Novartis A.G.Inventors: Ellen Marie Ajello, Michael Nelson Wilde, Yasuo Matsuzawa
-
Patent number: 6548542Abstract: Photodynamic therapy of conditions of the eye, especially those conditions characterized by unwanted neovasculature, such as age-related macular degeneration, results in enhanced visual acuity for treated subjects.Type: GrantFiled: April 28, 1999Date of Patent: April 15, 2003Assignees: QLT Inc., Novartis, A.G.Inventors: H. Andrew Strong, Julia Levy, Gustav Huber, Mario Fsadni
-
Patent number: 6395708Abstract: The present invention relates to a method for preventing irinotecan-induced or camptothecin-induced or camptothecin- analog-induced diarrhea by administering an effective amount of octreotide. In particular the invention concerns new methods, combination formulations and kits to prevent late diarrhea caused by irinotecan or camptothecin, or camptothecin-analog administration.Type: GrantFiled: August 25, 2000Date of Patent: May 28, 2002Assignees: Novartis, A.G., Pharmacia & Upjohn Co.Inventors: Langdon L. Miller, John David Rothermel, Hugh Michael O'Dowd
-
Patent number: 6159935Abstract: The present invention relates to a method for preventing irinotecan-induced or camptothecin-induced or camptothecin-analog-induced diarrhea by administering an effective amount of octreotide. In particular the invention concerns new methods, combination formulations and kits to prevent late diarrhea caused by irinotecan or camptothecin, or camptothecin-analog administration.Type: GrantFiled: November 29, 1999Date of Patent: December 12, 2000Assignees: Pharmacia & UpJohn Co., Novartis, A.G.Inventors: Langdon L. Miller, John David Rothermel, Hugh Michael O'Dowd
-
Patent number: 5962017Abstract: Pharmaceutical compositions comprising a cyclosporin, e.g. Ciclosporin or ?Nva!.sup.2 -Ciclosporin, in "microemulsion pre-concentrate" and microemulsion form. The compositions typically comprise (1.1) a C.sub.1-5 alkyl or tetrahydrofurfuryl di- or partial-ether of a low molecular weight mono- or poly-oxy-alkane diol, e.g. Transcutol or Glycofurol, as hydrophilic component. Compositions are also provided comprising a cyclosporin and (1.1) and, suitably, also a saccharide monoester, e.g. raffinose or saccharose monolaurate. Dosage forms include topical formulations and, in particular, oral dosage forms.Type: GrantFiled: February 17, 1998Date of Patent: October 5, 1999Assignee: Novartis GInventors: Birgit Hauer, Armin Meinzer, Ulrich Posanski, Friedrich Richter